首页> 外文期刊>World Journal of Urology >Management of the contralateral testicle in patients with unilateral testicular cancer
【24h】

Management of the contralateral testicle in patients with unilateral testicular cancer

机译:单侧睾丸癌患者对侧睾丸的管理

获取原文
获取原文并翻译 | 示例
       

摘要

Patients with a prior history of a germ cell tumor of the testicle are known to have an increased risk of development of a second germ cell tumor in the contralateral testicle. It is believed that all patients who develop a germ cell tumor of the testicle have a precursor lesion know as carcinoma in situ (CIS) or intratubular germ cell neoplasia. Approximately 50% of these patients will subsequently go on to develop a germ cell tumor in the testicle. A biopsy of the contralateral testicle in a patient with a previous history of a germ cell tumor of the testicle has been advocated by some, while others recommend a biopsy only in patients with other risk factors as well. The arguments for biopsy are that intervention may be used to prevent the development of a second germ cell tumor when CIS is detected. In this review we present the arguments for and against a biopsy of the contralateral testicle, review the techniques of biopsy as well as its complications, and discuss the interventions employed to prevent CIS from progressing.
机译:已知具有睾丸生殖细胞肿瘤病史的患者对侧睾丸发展第二生殖细胞肿瘤的风险增加。据信,所有发展为睾丸生殖细胞肿瘤的患者都有前体病变,称为原位癌(CIS)或肾小管内生殖细胞瘤。这些患者中约有50%随后将继续在睾丸中发展成生殖细胞肿瘤。一些人主张对有睾丸生殖细胞肿瘤病史的患者进行对侧睾丸活检,而另一些人也建议仅对具有其他危险因素的患者进行活检。活检的论点是,当检测到CIS时,可以使用干预措施来预防第二个生殖细胞肿瘤的发展。在这篇综述中,我们提出了对侧睾丸活检的支持和反对意见,对活检技术及其并发症进行了回顾,并讨论了用于阻止CIS发展的干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号